目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T4S1943 | Wnt/beta-catenin | ||
Kirenol (Kirel) 是分离自 Siegesbeckia orientalis 中的,具有抗氧化、抗炎、抗过敏、抗关节炎活性,可用于缓解疼痛的研究。 | |||
TN1040 | COX Antibacterial TGF-beta/Smad | ||
Skullcapflavone II 是从黄芩中提取的黄酮,具有抗炎作用。它对 M. aurum 和 M. bovisBCG 具有较强的抗菌活性。它还调节破骨细胞的分化、存活和功能。 | |||
T6S0117 | ERK | ||
Avicularin (Fenicularin) 具有抗过敏、抗炎、保肝、抗氧化、抗肿瘤等活性。它能通过调节 NF-κB(p65)、COX-2 和 PPAR-γ 的活性来改善人类肝细胞癌。在 LPS 刺激的 RAW 264.7 巨噬细胞中,它通过抑制 ERK 信号通路产生抗炎活性。 | |||
TN1712 | NF-κB S6 Kinase | ||
Gossypin 是一种从Hibiscus vitifolius 中分离得到的黄酮,能够抑制NF-κB 和 NF-κB 的调节基因表达。在小鼠原代骨髓细胞和 RAW264.7 细胞中,它也可抑制 RANKL 诱导的破骨细胞形成。它具有抗氧化、抗炎、抗癌、抗衰老、抗糖尿病和保护肝脏的活性。 | |||
TN1470 | Phosphatase MAO 5-HT Receptor | ||
Cassiaside B2 是蛋白酪氨酸磷酸酶1B (PTP1B) 和人单胺氧化酶A (hMAO-A) 的抑制剂。Cassiaside B2是 5-HT2C 受体的激动剂, 具有抗过敏活性。Cassiaside B2 是萘吡喃酮参比提取物(NRE)的有效成分之一。 | |||
T0219 | COX | ||
Valdecoxib (SC 65872) 是可口服的高选择性 COX-2抑制剂,对 COX-2 和 COX-1 的 IC50值分别为 5 nM 和 140 μM,可用于治疗骨关节炎、类风湿性关节炎以及痛经和经期症状。 | |||
T0977 | Glucocorticoid Receptor Others | ||
Medrysone (6α-Methyl-11β-hydroxyprogesterone) 是局部合成的糖皮质激素,具有代谢、抗炎和抗过敏特性,有潜力用于眼科的眼炎症研究。 | |||
T0094 | Glucocorticoid Receptor | ||
Budesonide (Pulmicort) 是吸入型糖皮质类固醇,是一种口服具有活性的糖皮质激素受体激动剂。它能够减小肺部肿瘤的体积,逆转 DNA 低度甲基化,调节基因的 mRNA 表达。它是能够用于哮喘的抗炎药。 | |||
T17214 | Others Antioxidant NF-κB | ||
Valencene (NSC-148969) 是一种从 Cyperus rotundus 中分离出来的倍半萜类化合物,是柑橘类水果和柑橘类衍生气味的香气成分。ValenceneValencene 具有抗过敏、抗炎、抗黑色素生成、和抗氧化活性。通过阻断 NF-κB 通路,Valencene 通过阻断 NF-κB 通路抑制 Th2 趋化因子和促炎性趋化因子的过度表达。 | |||
T5S1285 | Others | ||
(+)-(3R,8S)-Falcarindiol 是一种从胡萝卜中得到的聚乙炔,有抗炎、抗肿瘤和抗脂质过氧化活性。它具有抗分歧杆菌作用,对Mycobacterium tuberculosisH37Ra 的 MIC 和 IC50值分别为 24 μM 和 6 μM。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-00747 | Nectin-2 Protein, Human, Recombinant (His) | Human | HEK293 | ||
Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.
|
|||||
TMPY-00748 | Nectin-2 Protein, Human, Recombinant | Human | HEK293 | ||
Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.
|
|||||
TMPY-05446 | CD200 Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
CD200 (OX-2) is a cell surface glycoprotein that imparts immune privileges by suppressing alloimmune and autoimmune responses through its receptor, CD200R, expressed primarily on myeloid cells. Signals delivered through the CD200:CD200R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD200 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. The role of CD200-CD200R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD200-CD200R, microglia activation, and Parkinson's disease (PD). The ability of CD200 to suppress myeloid cell activation is critical for maintaining normal tissue homeostasis but may also enhance the survival of migratory neoplastic cells. CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD200 expression has been reported to be associated with poor prognosis in some human malignancies. Besides, CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-06295 | Nectin-2 Protein, Human, Recombinant (hFc & Avi), Biotinylated | Human | HEK293 | ||
Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.
|
|||||
TMPY-03036 | Nectin-2 Protein, Rat, Recombinant (His) | Rat | HEK293 | ||
Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.
|
|||||
TMPY-06383 | Nectin-2 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.
|
|||||
TMPY-02561 | Nectin-2 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.
|
|||||
TMPY-01150 | Nectin-2 Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.
|
|||||
TMPY-00746 | Nectin-2 Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.
|
|||||
TMPJ-00323 | Nectin-2 Protein, Mouse, Recombinant (hFc) | Mouse | Human Cells | ||
CD112 is a type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. It comprises one Ig-like V-type domain and two Ig-like C2-type domains in the extracellular region. The V domain is believed to mediate nectin binding to its ligands. Nectin2 is known to bind the pseudorabies virus, and herpes simplex virus2 (HSV2), involving in cell to cell spreading of these viruses. It does not bind poliovirus. As a homophilic adhesion molecule, CD112 is found concentrated in adherens junctions, and exists on neurons, endothelial cells,epithelial cells and fibroblasts. CD112 has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 mediates cytotoxicity and cytokine secretion by T and NK cells. The costimulatory responses may be a critical component in allergic reactions and may therefore become targets for anti-allergic therapy.
|
|||||
TMPY-01071 | CD200 Protein, Human, Recombinant (His) | Human | HEK293 | ||
CD200 (OX-2) is a cell surface glycoprotein that imparts immune privileges by suppressing alloimmune and autoimmune responses through its receptor, CD200R, expressed primarily on myeloid cells. Signals delivered through the CD200:CD200R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD200 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. The role of CD200-CD200R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD200-CD200R, microglia activation, and Parkinson's disease (PD). The ability of CD200 to suppress myeloid cell activation is critical for maintaining normal tissue homeostasis but may also enhance the survival of migratory neoplastic cells. CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD200 expression has been reported to be associated with poor prognosis in some human malignancies. Besides, CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-03380 | CD200 Protein, Rhesus, Recombinant (hFc) | Rhesus | HEK293 | ||
CD200 (OX-2) is a cell surface glycoprotein that imparts immune privileges by suppressing alloimmune and autoimmune responses through its receptor, CD200R, expressed primarily on myeloid cells. Signals delivered through the CD200:CD200R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD200 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. The role of CD200-CD200R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD200-CD200R, microglia activation, and Parkinson's disease (PD). The ability of CD200 to suppress myeloid cell activation is critical for maintaining normal tissue homeostasis but may also enhance the survival of migratory neoplastic cells. CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD200 expression has been reported to be associated with poor prognosis in some human malignancies. Besides, CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-06791 | CD200 Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
CD200 (OX-2) is a cell surface glycoprotein that imparts immune privileges by suppressing alloimmune and autoimmune responses through its receptor, CD200R, expressed primarily on myeloid cells. Signals delivered through the CD200:CD200R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD200 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. The role of CD200-CD200R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD200-CD200R, microglia activation, and Parkinson's disease (PD). The ability of CD200 to suppress myeloid cell activation is critical for maintaining normal tissue homeostasis but may also enhance the survival of migratory neoplastic cells. CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD200 expression has been reported to be associated with poor prognosis in some human malignancies. Besides, CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-03595 | CD200 Protein, Rhesus, Recombinant (His) | Rhesus | HEK293 | ||
CD200 (OX-2) is a cell surface glycoprotein that imparts immune privileges by suppressing alloimmune and autoimmune responses through its receptor, CD200R, expressed primarily on myeloid cells. Signals delivered through the CD200:CD200R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD200 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. The role of CD200-CD200R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD200-CD200R, microglia activation, and Parkinson's disease (PD). The ability of CD200 to suppress myeloid cell activation is critical for maintaining normal tissue homeostasis but may also enhance the survival of migratory neoplastic cells. CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD200 expression has been reported to be associated with poor prognosis in some human malignancies. Besides, CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-05638 | CD200 Protein, Human, Recombinant (hFc & Avi) | Human | HEK293 | ||
CD200 (OX-2) is a cell surface glycoprotein that imparts immune privileges by suppressing alloimmune and autoimmune responses through its receptor, CD200R, expressed primarily on myeloid cells. Signals delivered through the CD200:CD200R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD200 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. The role of CD200-CD200R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD200-CD200R, microglia activation, and Parkinson's disease (PD). The ability of CD200 to suppress myeloid cell activation is critical for maintaining normal tissue homeostasis but may also enhance the survival of migratory neoplastic cells. CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD200 expression has been reported to be associated with poor prognosis in some human malignancies. Besides, CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-01160 | CD200 Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
CD200 (OX-2) is a cell surface glycoprotein that imparts immune privileges by suppressing alloimmune and autoimmune responses through its receptor, CD200R, expressed primarily on myeloid cells. Signals delivered through the CD200:CD200R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD200 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. The role of CD200-CD200R signaling in immune regulation of the central nervous system has become a popular field of research in recent years. Many studies have shown that there is a close correlation between CD200-CD200R, microglia activation, and Parkinson's disease (PD). The ability of CD200 to suppress myeloid cell activation is critical for maintaining normal tissue homeostasis but may also enhance the survival of migratory neoplastic cells. CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 has been characterized as an important immunoregulatory molecule, increased expression of which can lead to decreased transplant rejection, autoimmunity, and allergic disease. Elevated CD200 expression has been reported to be associated with poor prognosis in some human malignancies. Besides, CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|